Urothelial Carcinoma
Conditions
Interventions
Gold Standard:Cases of urothelial carcinoma and other tumors are diagnosed through pathological diagnosis, while other diseases such as urinary tract stones and prostate hyperplasia are diagnosed thro
Index test:Human FGFR3/TERT Gene Mutation and ONECUT2/VIM Gene methylation Detection Kit (PCR Fluorescent Probe Method),DNA mutation analysis
Human FGFR3/TERT Gene Mutation and ONECUT2/VIM Gene methylation Detection Kit (PCR Fluorescent Probe Method),DNA methylation analysi
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
19 Years to 92 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old, gender is not limited; (2) can provide not less than 100mL morning urine sample; (3) Sign the informed consent document; (4) One of the following conditions must be met: a. Subjects with pathologically confirmed urothelial carcinoma; b. Subjects who have been pathologically diagnosed with malignant tumors other than urothelial carcinoma; c. Subjects clinically diagnosed with benign urinary diseases, including urinary calculi, prostatic hyperplasia, renal cysts or other benign lesions; d. Subjects for whom the clinician recommends cystoscopy, ureteroscopy, or transurethral resection of bladder tumors.
Exclusion criteria
Exclusion criteria: Subjects with any of the following criteria were excluded from the study: (1) Previous history of malignant tumor; (2) Subjects with other systemic tumors combined with urothelial carcinoma; (3) Unable to sample or sample unqualified; (4) Failure to sign the informed consent document; (5) Subjects that the investigator considers it inappropriate to continue to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA mutation analysis;DNA methylation analysis;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactDingwei Ye
Fudan University Shanghai Cancer Center
Outcome results
None listed